Long-acting protein drugs for the treatment of ocular diseases

Long-acting protein drugs for the treatment of ocular diseases

Retinal vascular disease treatments involve frequent pharmacological intraocular administrations. Here the authors present a method to increase the half-life of injected drugs by fusing these to a hyaluronan-binding peptide, which might lead to less frequent retinal disease treatments.

Bibliographic Details
Main Authors: Joy G. Ghosh, Andrew A. Nguyen, Chad E. Bigelow, Stephen Poor, Yubin Qiu, Nalini Rangaswamy, Richard Ornberg, Brittany Jackson, Howard Mak, Tucker Ezell, Vania Kenanova, Elisa de la Cruz, Ana Carrion, Bijan Etemad-Gilbertson, Roxana Garcia Caro, Kan Zhu, Vinney George, Jirong Bai, Radhika Sharma-Nahar, Siyuan Shen, Yiqin Wang, Kulandayan K. Subramanian, Elizabeth Fassbender, Michael Maker, Shawn Hanks, Joanna Vrouvlianis, Barrett Leehy, Debby Long, Melissa Prentiss, Viral Kansara, Bruce Jaffee, Thaddeus P. Dryja, Michael Roguska
Format: Article
Language:English
Published: Nature Publishing Group 2017-03-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/ncomms14837

Internet

https://doi.org/10.1038/ncomms14837

Similar Items